Reynders Mc Veigh Capital Management, LLC Novo Nordisk A S Transaction History

Reynders Mc Veigh Capital Management, LLC

$1.89 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$102.11 - $135.92 $44,213 - $58,853	-433 Reduced 0.1%	448,673 $57.6 Million
Q4 2023 Feb 07, 2024	SELL	$87.78 - $105.45 $3.52 Million - $4.23 Million	-40,118 Reduced 8.2%	449,106 $46.5 Million
Q3 2023 Nov 09, 2023	BUY	$90.94 - $199.54 $21.4 Million - $46.9 Million	235,062 Added 92.49%	489,224 $44.5 Million
Q2 2023 Aug 09, 2023	SELL	$155.98 - $172.65 $3.09 Million - $3.42 Million	-19,836 Reduced 7.24%	254,162 $41.1 Million
Q1 2023 May 03, 2023	SELL	$132.34 - $159.14 $2.22 Million - $2.67 Million	-16,804 Reduced 5.78%	273,998 $43.6 Million
Q4 2022 Feb 10, 2023	BUY	$102.55 - $135.33 $242,838 - $320,461	2,368 Added 0.82%	290,802 $39.4 Million
Q3 2022 Nov 08, 2022	BUY	$95.28 - $116.93 $1.59 Million - $1.96 Million	16,731 Added 6.16%	288,434 $28.7 Million
Q2 2022 Aug 05, 2022	BUY	$103.24 - $121.81 $509,695 - $601,375	4,937 Added 1.85%	271,703 $30.3 Million
Q1 2022 May 11, 2022	BUY	$93.1 - $112.54 $1.71 Million - $2.06 Million	18,332 Added 7.38%	266,766 $29.6 Million
Q4 2021 Feb 11, 2022	BUY	$95.88 - $117.08 $1.68 Million - $2.05 Million	17,479 Added 7.57%	248,434 $27.8 Million
Q3 2021 Nov 15, 2021	BUY	$84.42 - $106.62 $897,722 - $1.13 Million	10,634 Added 4.83%	230,955 $22.2 Million
Q2 2021 Aug 12, 2021	BUY	$67.66 - $84.76 $1.26 Million - $1.58 Million	18,665 Added 9.26%	220,321 $18.5 Million
Q1 2021 May 07, 2021	BUY	$67.06 - $75.82 $1.52 Million - $1.71 Million	22,602 Added 12.62%	201,656 $13.6 Million
Q4 2020 Feb 10, 2021	BUY	$63.89 - $73.8 $624,269 - $721,099	9,771 Added 5.77%	179,054 $12.5 Million
Q3 2020 Oct 28, 2020	BUY	$63.69 - $70.22 $1.59 Million - $1.76 Million	25,003 Added 17.33%	169,283 $11.8 Million
Q2 2020 Aug 14, 2020	BUY	$58.54 - $67.94 $1.58 Million - $1.84 Million	27,049 Added 23.07%	144,280 $9.45 Million
Q1 2020 May 13, 2020	BUY	$49.46 - $64.78 $1.06 Million - $1.39 Million	21,425 Added 22.36%	117,231 $7.06 Million
Q4 2019 Feb 14, 2020	BUY	$49.86 - $58.26 $594,081 - $694,167	11,915 Added 14.2%	95,806 $5.55 Million
Q3 2019 Nov 08, 2019	BUY	$47.54 - $53.43 $482,293 - $542,047	10,145 Added 13.76%	83,891 $4.34 Million
Q2 2019 Aug 06, 2019	BUY	$46.79 - $52.47 $1.21 Million - $1.36 Million	25,925 Added 54.21%	73,746 $3.76 Million
Q1 2019 May 10, 2019	BUY	$46.36 - $52.63 $407,040 - $462,091	8,780 Added 22.49%	47,821 $2.5 Million
Q4 2018 Feb 14, 2019	SELL	$41.54 - $47.25 $348,811 - $396,758	-8,397 Reduced 17.7%	39,041 $1.8 Million
Q3 2018 Nov 26, 2018	SELL	$46.76 - $51.24 $257,367 - $282,024	-5,504 Reduced 10.4%	47,438 $2.24 Million
Q2 2018 Aug 09, 2018	SELL	$44.29 - $50.42 $204,531 - $232,839	-4,618 Reduced 8.02%	52,942 $2.44 Million
Q1 2018 Jul 26, 2018	BUY	$48.49 - $58.14 $2.65 Million - $3.18 Million	54,725 Added 1930.34%	57,560 $2.84 Million
Q1 2018 May 03, 2018	SELL	$48.49 - $58.14 $3.25 Million - $3.9 Million	-67,107 Reduced 95.95%	2,835 $57.6 Million
Q4 2017 Feb 06, 2018	SELL	$47.53 - $53.73 $718,035 - $811,699	-15,107 Reduced 17.76%	69,942 $0
Q3 2017 Nov 09, 2017	SELL	$41.15 - $49.22 $508,819 - $608,605	-12,365 Reduced 12.69%	85,049 $4.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	97,414	97,414 $4.18 Million

Others Institutions Holding NVO

# of Institutions

1,957

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

Jennison Associates LLC

20.2M
Shares

$1.76 Billion
1.5% of portfolio
Morgan Stanley New York, NY

14.4M
Shares

$1.26 Billion
0.13% of portfolio
Bank Of America Corp Charlotte, NC

14.3M
Shares

$1.25 Billion
0.14% of portfolio
Ken Fisher Fisher Asset Management, LLC | Camas, Wa

13.3M
Shares

$1.16 Billion
0.65% of portfolio
Fayez Sarofim & CO Houston, TX

12.2M
Shares

$1.07 Billion
3.76% of portfolio

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.

Account